The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global virus filtration market was valued at US$ 3.57 Billion in 2021.
We expect the global virus filtration market to exhibit a CAGR of 11.20% during 2022-2027.
The high prevalence of numerous chronic diseases, along with the growing adoption of virus filtration method to aid in manufacturing various biotherapeutic products, is primarily driving the global virus filtration market.
The sudden outbreak of the COVID-19 pandemic has led to the rising demand for potential therapies to treat the coronavirus-infected patients under critical conditions, thereby increasing the application for virus filtration in the convalescent plasma for reducing inflammatory mediators.
Based on the product, the global virus filtration market can be segmented into consumables, instruments, and services, where consumables hold the majority of the total market share.
Based on the application, the global virus filtration market has been divided into biologicals, medical devices, water purification, air purification, and others. Currently, biologicals exhibit a clear dominance in the market.
Based on the end use, the global virus filtration market can be categorized into biopharmaceutical and biotechnology companies, contract research organizations, academic institutes and research laboratories, and others. Among these, biopharmaceutical and biotechnology companies account for the majority of the global market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global virus filtration market include Asahi Kasei Medical Co. Ltd., Charles River Laboratories, Inc., Clean Cells, Danaher Corporation, Merck KGaA, Sartorius AG, and Thermo Fisher Scientific Inc.
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at